~~<i id='706FEC9C2F'><strike id='706FEC9C2F'><tt id='706FEC9C2F'><pre id='706FEC9C2F'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：comprehensive 2025-10-01 21:54:37 Page View：786

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approves first treatment for ultra
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

The problems with dementia villages

AdobeRecently,dementiavillageshavegainedpopularityinEuropeandAustraliaasanall-in-onesolutiontocaring

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

ActiGraph execs on goal of drug approvals with digital endpoints

JeremeyWyattActiGraphAsdrugmakerswadeintousingdigitalhealthtechnologies,ActiGraphhasmadeitsmissionto